Large vessel vasculitides

Current Opinion in Rheumatology

Volumn 10, Issue 1, 1998, Pages 18-28

  Cid, Maria C ^a   Font, Carme ^a   Coll Vinent, Blanca ^a   Grau, Josep M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CELL ADHESION MOLECULE; CORTICOSTEROID; HLA ANTIGEN CLASS 1;

AORTA ARCH SYNDROME; ARTERY WALL; BLOOD VESSEL REACTIVITY; CELL ACTIVATION; CELL DIFFERENTIATION; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE ASSOCIATION; GEOGRAPHIC DISTRIBUTION; GIANT CELL ARTERITIS; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; MACROPHAGE; MOLECULAR RECOGNITION; MUSCULOSKELETAL DISEASE; NEOVASCULARIZATION (PATHOLOGY); PATHOGENESIS; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RHEUMATIC POLYMYALGIA; SYNOVITIS; T LYMPHOCYTE; TREATMENT OUTCOME; VASCULITIS;

ANGIOGRAPHY; DIAGNOSIS, DIFFERENTIAL; HUMANS; TAKAYASU'S ARTERITIS; TEMPORAL ARTERITIS;

EID: 0031964183     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199801000-00004     Document Type: Review

References (101)

1. Lie JT: Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 1995, 21:883-909.
2. Kerr GS: Takayasu's arteritis. Curr Opin Rheumatol 1994, 6:32-38.
3. Hunder GG: Giant-cell arteritis and polymyalgia rheumatica. Med Clin •• North Am 1897, 81:195-219. Comprehensive in-depth review including the most significant epidemiologic, clinical, pathologic, and pathogenetic aspects of GCA and PMR. Classic knowledge, to which the author has largely contributed, is finely combined with the newest data
4. Lie JT: Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathological documentation. Semin Arthritis Rheum 1995, 24:422-431.
5. Ostberg G: Morphological changes in the large arteries in polymyalgia arteritica. Acta Med Scand 1972, 533:135-164.
6. Evans JM, O'Falloon WM, Hunder GG: Increased Incidence of aortic aneurysm and dissection in giant-cell (temporal) arteritis. Ann Intern Med 1995, 122:502-507.
7. Klein RG, Hunder GG, Stanson AW, Sheps SJ: Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975, 83:806-812.
8. Hoffman GS: Takayasu arteritis: lessons from the American National •• Institutes of Health experience. Int J Cardiol 1996, 54(suppl):S99-S102. In addition to a complete summary of the author's prospective experience in the treatment of patients with TA, this review addresses important questions about the accuracy of current disease activity assessment systems and the effectiveness of therapeutic regimens available at present.
9. Ishikawa K, Maetani S: Long-term outcome for 120 Japanese patients with Takayasu's disease: clinical and statistical analyses of related prognostic factors. Circulation 1995, 90:1855-1860.
10. Nakao K, Ikeda M, Kimata SI, Niitani H, Miyahara M, Ishimi ZI, Hashiba K, Takeda Y, Ozawa T, Matsushita S, Kuramochi M: Takayasu's arteritis: clinical report of eighty-four cases and immunological studies of seven cases. Circulation 1967, 35:1141-1155.
11. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS: Takayasu's arteritis. Ann Intern Med 1994, 120:919-929.
12. Lupi-Herrera E, Sanchez-Torres G, Marchushamer J, Mispireta J, Horwitz S, Vela JE: Takayasu's arteritis: clinical study of 107 cases. Am Heart J 1977, 93:94-103.
13. Numano F: Differences In clinical presentation and outcome in different countries for Takayasu's arteritis. Curr Opin Rheumatol 1997, 9:12-15.
14. Hata A, Noda M, Moriwaki R, Numano F: Angiographic findings of •• Takayasu arteritis: new classification. Int J Cardiol 1996, 54(suppl):S155-S163. The systematic application of the new angiographic classification of TA arterial lesions has allowed the identification of variations in the distribution pattern of vascular involvement in different geographic areas.
15. Michel BA, Arend WP, Hunder GG: Clinical differentiation between • giant-cell (temporal) arteritis and Takayasu's arteritis. J Rheumatol 1996, 23:106-111. Takayasu's arteritis is being increasingly diagnosed in patienta older than 40 years. The authors describe clinical findings useful in distinguishing GCA from TA. The presence of signs or symptoms of upper limb occlusion increases the likelihood of TA. Conversely, white race, scalp tenderness, clinical abnormalities in temporal arteries, and shoulder stiffness are significantly more frequent in patients with GCA.
16. Baldursson O, Steinsson K, Bjomsson J: Giant cell arteritis in Iceland: an epidemiologic and histologic analysis. Arthritis Rheum 1994, 37:1007-1012.
17. Noltorp S, Svensson B: High incidence of polymyalgia rheumatica and giant cell arteritis in a Swedish community. Clin Exp Rheumatol 1991, 9:351-354.
18. Nordborg E, Bengtsson BA: Epidemiology of biopsy-proven giant-cell arteritis. J Intern Med 1990, 227:233-236.
19. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG: The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995, 123:192-194.
20. Nesher G, Rubinow A, Sonnenblick M: Trends in clinical presentation in temporal arteritis in Israel: reflection of Increased physician awareness. Clin Rheumatol 1996, 15:483-485.
21. Weyand CM, Goronzy JJ: Giant cell arteritis is an antigen-driven disease. Rheum Clin North Am 1995, 21:1027-1039.
22. Evans J, Hunder GG: The implications of recognizing large-vessel involvement in elderly patients with giant-cell arteritis. Curr Opin Rheumatol 1997, 9:37-40.
23. Lowenstein MB, Bridgeford PH, Vasey FB, Germain BF, Espinoza LR: Increased frequency of HLA-DR3 and DR4 In polymyalgia rheumaticagiant cell arteritis. Arthritis Rheum 1983, 26:925-927.
24. Richardson JE, Gladman DD, Fam A, Keystone EC: HLA-DR4 in giant cell arteritis: association with polymyalgia rheumatica syndrome. Arthritis Rheum 1987, 30:1293-1297.
25. Bignon JD, Barrier J, Soulillou JP, Martin PH, Grolleau JY: HLA-DR4 and giant cell arteritis. Tissue Antigens 1984, 24:60-62.
26. Cid MC, Ercilla MG, Vilaseca J, Sanmarti J, Villalta J, Ingelmo M, Urbano-Marquez A: Polymyalgia rheumatica: a syndrome associated with the HLA-DR4 antigen. Arthritis Rheum 1988, 31:678-682.
27. Uddharnmar A, Nilsson Sojka B, Rantapaa-Dahlqvist S: HLA antigens In polymyalgia rheumatica in Northern Sweden. Clin Rheumatol 1996, 15:486-490.
28. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ: The HLA-DRB1 locus as a genetic component In giant cell arteritis: mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 1992, 90:2355-2361.
29. Weyand CM, Hunder NNH, Hicok KC, Hunder GG, Goronzy JJ: HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatold arthritis. Arthritis Rheum 1994, 37:514-520.
30. Boiardi L, Salvarani C, Macchioni P, Casadei Maldini M, Mancini R, Beltrandi E, Portioli I: CD8 lymphocyte subsets In active polymyalgia rheumatica: comparison with elderly-onset and adult rheumatoid arthritis and influence of prednisone therapy. Br J Rheumatol 1996, 35:642-648.
31. Dasgupta B, Duke O, Timms AM, Pitzalis C, Panayi GS: Selective depletion and activation of CD8 lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 1989, 48:307-311.
32. Roblot P, Morel F, Lelievre E, Gascan H, Wijdeness J, Lecron JC: Serum cytokines and cytokine receptor levels In patients with giant cell arteritis during corticotherapy. J Rheumatol 1996, 23:408-410.
33. Salvarani C, Boiardi L, Macchioni PL, Rossi F, Tartoni P, Casadei Maldini M, Mancini R, Bettrandi E, Portioli I: Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment In polymyalgia rheumatica and giant-cell arteritis. Ann Rheum Dis 1995, 54:640-644.
34. Carson CW, Beall DL, Hunder GG, Johnson CM, Newman W: Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 1993, 20:809-814.
35. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM: Correlation between interleukin-6 production and disease activity In polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993, 36:1286-1294.
36. Martinez-Taboada VM, Goronzy JJ, Weyand CM: Clonally expanded CD8 T cells In patients with polymyalgia rheumatica and giant cell arteritis. Clin Immunol immunopathol 1996, 79:263-270.
37. Cid MC, Campo E, Ercilla G, Palacin A, Vilaseca J, Villatta J, Ingelmo M: Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Arthritis Rheum 1989, 32:884-893.
38. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ: Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994, 121:484-491.
39. Weyand CM, Shonberger J, Oppitz U, Hunder NNH, Hicock KC, Goronzy JJ: Distinct vascular lesions in giant cell arteritls share identical T cell clonotypes. J Exp Med 1994, 179:951-960.
40. Martinez-Taboada V, Hunder NNH, Hunder GG, Weyand CM, Goronzy JJ: • Recognition of tissue residing antigen by T cells In vasculitic lesions of giant cell arteritis. J Mol Med 1996, 74:695-703. T cells with identical T-cell receptor-β chain sequences can be identified in different segments of an involved artery or in right and left temporal arteries from the same individual. However, T-cell clones derived from specimens of different patients do not disclose sequence homologies. Interestingly, although no definitive conclusions can be drawn owing to the small amount of individuals studied, T-cell clonotypes dominant in lesions exhibit proliferative activity toward antigens present in temporal arteries from patients with GCA and PMR but not toward those present in temporal arteries from individuals with unrelated diseases.
41. Wagner AD, Bjömsson J, Bartley GB, Goronzy JJ, Weyand CM: • Interferon-γ-producing T cells In giant cell vasculitis represent a minority of tissue Infiltrating cells and are located distant from the site of pathology. Am J Pathol 1996, 148:1925-1933. These authors show that potentially disease-relevant T cells are scarce and are usually located at the adventitial layer.
42. Weinberg JB, Hubbs MM, Misukonis MA: Recombinant human γIFN Induces human monocyte polykarion formation. Proc Natl Acad Sci U S A 1984, 81:4554-4557.
43. Adams DO: The biology of the granulomas. In The Pathology of Granulomas. Edited by loachim HL New York: Raven Press; 1983:1-20.
44. Weyand CM, Tetzlaff N, Bjömsson J, Brack A, Younge B, Goronzy JJ: •• Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997, 40:19-26. Giant cell (temporal) arteritis typically has a high variability in clinical presentation. Data presented in this paper support that different patterns of cytokine expression may account for different disease expression forms of the disease. Patients with prominent cranial symptoms (jaw claudication or visual loss) and whose biopsy specimens show a prominent granulomatous reaction with giant cells produce more interferon gamma in their lesions than patients presenting with fever and systemic complaints. Patients with PMR produce higher levels of interleukin-2 mRNA.
45. Sorbi D, French DL, Nuovo GJ, Kew RR, Arbeit LA, Gruber BL: Elevated levels of 92-Kd type IV collagenase (matrix metalloprotelnase 9) In giant cell arteritis. Arthritis Rheum 1996, 39:1747-1753.
46. Nikkari ST, Hoyhtya M, Isola J, Nikkari T: Macrophages contain 92-Kd gelatinese (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996, 149:1427-1433.
47. Weyand CM, Wagner AD, Bjömsson J, Goronzy JJ: Correlation of the •• topographical arrangement and the functional pattern of tissue-infiltrating macrophages In giant cell arteritis. J Clin Invest 1996, 98:1642-1649. In this study, the authors propose that tissue-infiltrating macrophages are functionally heterogeneous and are spatially organized. Adventitial macrophages actively produce interleukin-1, interleukin-6, and TGF-β and may contribute to the systemic inflammatory reaction and to the recruitment of inflammatory cells. Macrophages located at the tunica media produce matrix metalloproteases, allowing the progression of inflammatory cells, and those at the intimai layer produce nitric oxide synthase, which may contribute to vessel damage.
48. Font C, Cebrian M, Cid MC, Coll-Vinent B, Sánchez E, López-Soto A, Grau JM: Polymorphonuclear leukocytes and E-selectin expression In Inflammatory lesions of giant-cell arteritis. Arthritis Rheum 1996, 39(suppl):S67.
49. Kasama T, Strieter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL: Interferon Y modulates the expression of neutrophil-derived chemokines. J Investigative Med 1995, 43:58-67.
50. Coll-Vinent B, Cebrián M, Cid MC, Font C, Juan M, Yagüe J, Urbano-Márquez A, Grau JM: Dynamic pattern of endothelial cell adhesion molecule expression In muscle and perineural vessels from patients with classical polyarteritis nodosa. Arthritis Rheum 1998, in press.
51. Mantovani A, Bussolino F, Dejana E: Cytokine regulation of endothelial cell function. FASEB J 1992, 6:2591-2599.
52. Mantovani A, Bussolino F, Introna M: Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today 1997, 18:231-240.
53. Cid MC: New developments in the pathogenesls of systemic vasculitis. Curr Opin Rheumatol 1996, 8:1-11.
54. Cid MC, Cebrián M, Font C, Coll-Vinent B, Sánchez E, López-Soto A, Urbano-Márquez A, Grau JM: Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis (GCA). Arthritis Rheum 1997, 40(suppl)S68.
55. Park JH: Conventional and CT angiographic diagnosis of Takayasu • arteritis. Int J Cardiol 1996, 54(suppl):S167-S171. Review of the contribution of spiral computed tomographic angiography in precontrast, arterial, and delayed phase to the evaluation of aortic wall abnormalities and their correlation with pathologic findings.
56. Kovacs EJ, di Pietro LA: Fibrogenic cytokines and connective tissue production. FASEB J 1994, 8:854-861.
57. Cid MC, Font C, Oristrell J, López-Soto A, Coll-Vinent B, Vilaseca J, Urbano-Márquez A, Grau JM: Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998, in press.
58. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK: Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993, 91:977-985.
59. Salvarani C, Macchioni P, Boiardi L: Polymyalgia rheumatica. Lancet •• 1997, 350:43-47. Excellent review on the most relevant aspects of PMR, including the authors' contributions over the past recent years.
60. Gonzalez-Gay MA, Rodriguez-Valverde V, Blanco R, Fernández-Sueiro JL, Armona J, Figueroa M, Martinez-Taboada VM: Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. Arch Intern Med 1997, 157:317-320.
61. Healey LA: Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984, 13:322-328.
62. Behn AR, Perera T, Myles AB: Polymyalgia rheumatica and corticosteroids: how much and for how long? Ann Rheum Dis 1983, 42:374-378.
63. Wagner AD, Goronzy JJ, Weyand CM: Functional profile of tissue Infiltrating and circulating CD68+ cells in giant cell arteritis: evidence for two components of the disease. J Clin Invest 1994, 94:1134-1140.
64. Al-Hussaini AS, Swannell AJ: Peripheral joint involvement in polymyalgia rheumatica: a clinical study of 56 cases. Br J Rheumatol 1985, 24:27-30.
65. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT: Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982, 97:672-680.
66. Meliconi R, Pulsatelli L, Uguccioni M, Salvarani C, Macchioni P, Melchiorri •• C, Focherini C, Frizziero L, Facchini A: Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica: quantitative analysis and influence of corticosterold treatment Arthritis Rheum 1996, 39:1199-1207. This is the first immunopathologic study performed on PMR synovitis. Inflammatory infiltrates are mainly constituted by macrophages and T lymphocytes with scattered neutrophils and virtually no B lymphocytes, γ/δ T cells, or natural killer cells.
67. Meliconi R, Pulsatelli L, Melchiorri C, Frizziero L, Salvarani C, Macchioni P, •• Uguccioni M, Focherini MC, Facchini A: Synovial expression of cell adhesion molecules in polymyalgia rheumatica. Clin Exp Immunol 1997, 107:494-500. Neovascularization and endothelial adhesion molecule expression are prominent in PMR synovitis specimens, and they may probably contribute to the recruitment of inflammatory cells.
68. Deal CL, Meenan RF, Goldenberg DL, Anderson JJ, Sack B, Pastan RS, Cohen AS: The clinical features of elderly-onset rheumatoid arthritis. Arthritis Rheum 1985, 28:987-994.
69. Healey LA, Sheets P: The relation of polymyalgia rheumatica to rheumatoid arthritis. J Rheumatol 1988, 15:750-752.
70. Haworth S, Ridgeway J, Stewart I, Dyer PA, Pepper L, Ollier W: Polymyalgia rheumatica is associated with both HLA-DRB1*0401 and DRB1*0404. Br J Rheumatol 1996, 35:632-635.
71. Ellis ME, Ralston S: The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome. Ann Rheum Dis 1983, 42:168-170.
72. Font C, Cid MC, Coll-Vinent B, López-Soto A, Grau JM: Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 1997, 36:251-254.
73. Liu GT, Glaser JS, Schatz NJ, Smith JL: Visual morbidity In giant cell arteritis. Ophthalmology 1994, 101:1779-1785.
74. Aiello PD, Trautman JC, McPhee TJ, Kunselman AR, Hunder GG: Visual prognosis in giant cell arteritis. Ophthalmology 1993, 100:550-555.
75. Fauchald P, Rygvold O, Oytesse B: Temporal arteritis and polymyalgia rheumatica: clinical and biopsy findings. Ann Intern Med 1972, 77:845-852.
76. Evans JM, Bowles CA, Bjömsson J, Mullany CJ, Hunder GG: Thoracic aortic aneurysm and rupture in giant-cell arteritis: a descriptive study of 41 cases. Arthritis Rheum 1994, 37:1539-1547.
77. Brack A, Rittner HL, Younge BR, Kaltschmidt C, Weyand CM, Goronzy JJ: •• Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997, 99:1642-1649. In this elegantly designed study, the authors analyze the effects of corticosteriods on cytokine gene expression in human temporal arteries from patients with GCA engrafted into severe combined immunodeficiency diseased mice.
78. Huston KA, Hunder GG, Lie JT: Temporal arteritis: a 25-year epidemiologic, clinical and pathologic study. Ann Intern Med 1978, 88:162-167.
79. Ayoub WT, Franklin CM, Torretti D: Polymyalgia rheumatica: duration of therapy and long-term outcome. Am J Med 1985, 79:309-315.
80. Caplanne D, Le Parc JM, Alexandre JA: Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 1996,55:403-404.
81. Tellus MB, Byron K, Sachthep S, Ratnaike S, Wicks I: Cytokines In polymyalgia rheumatica. Arthritis Rheum 1996, 39:1264-1265.
82. Federici AB, Fox RI, Espinoza LR, Zimmerman TS: Elevation of von Willebrand factor Is Independent of erythrocyte sedimentation rate and persists after glucocorticoid treatment In giant cell arteritis. Arthritis Rheum 1984, 27:1046-1049.
83. Cid MC, Monteagudo J, Oristrell J, Vilaseca J, Pallarés L, Cervera R, Font C, Font J, Ingelmo M, Urbano-Márquez A: Von Willebrand factor in the outcome of temporal arteritis. Ann Rheum Dis 1996, 55:927-930.
84. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW, et al.: The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990, 33:1129-1134.
85. Eichhorn J, Sima D, Thiele B, Lindschau C, Turowski A, Schmidt H, Schneider W, Haller H, Luft FC: Anti-endothelial cell antibodies in Takayasu's arteritis. Circulation 1996, 94:2396-2401.
86. Sharma BK, Jain S, Sugar S: Systemic manifestations of Takayasu's arteritis: the expanding spectrum. Int J Cardiol 1996, 54(suppl):S149-S154.
87. Schaufelberger C, Stemme S, Andersson R, Hansson GK: T lymphocytes in giant cell arteritic lesions are polyclonal cells expressing α/β type receptors and VLA-1 integrin receptors. Clin Exp Immunol 1993, 91:421-428.
88. Mehra NK, Rajalingam R, Sagar S, Jain S, Sharma BK: Direct role of HLA-• B5 in Influencing susceptibility to Takayasu aortoarteritis. Int J Cardiol 1996, 54(suppl):S71-S79. Disease association with HLA genes seems to vary in different settings. In India, TA genetic predisposition appears to be associated with HLA-B5 by both serologic and molecular techniques.
89. Kimura A, Kitamura H, Date Y, Numano F: Comprehensive analysis of • HLA genes in Takayasu arteritis in Japan. Int J Cardiol 1996, 54(suppl):S61-S69. The authors show a significantly increased frequency of the HLA genes B52 and B39.2 among Japanese patients with TA by both serologic and DNA typing methods.
90. Waem AU, Andersson P, Hemmingsson A: Takayasu's arteritis: a hospital region based study on occurrence, treatment and prognosis. Angiology 1983, 34:311-326.
91. Sharma BK, Jain S, Suri S, Numano F: Diagnostic criteria for Takayasu • arteritis. Int J Cardiol 1996, 54(suppl):S141-S147. Variations in the distribution of Takayasu's arteritis lesions.
92. Ishikawa K: Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu's arteriopathy. J Am Coll Cardiol 1988, 12:964-972.
93. Lie JT: Isolated pulmonary Takayasu arteritis: clinicopathologic characteristics. Mod Pathol 1996, 9:469-474.
94. Suwanwela N, Pryachon C: Takayasu arteritis in Thailand: clinical and •• imaging features. Int J Cardiol 1996, 54(suppl):S117-S134. Comparative analysis of imaging techniques performed in 63 patients shows that invasive angiography is the most sensitive method for the detection of TA lesions in any vascular territory. Computed tomography, magnetic resonance imaging, and magnetic resonance angiography are less sensitive in detecting vascular lesions, particularly in smaller branches, but are able to provide interesting details about intraluminal clots, vessel wall, and surrounding tissue.
95. Park JH, Chung JW, Im JG, Kim SK, Park YB, Han MC: Takayasu's arteritis: evaluation of mural changes in the aorta and pulmonary artery with CT angiography. Radiology 1995, 196:89-93.
96. Raninen RO, Kupari MM, Pamilo MS, Pajari RI, Poutanen VP, Hekali PE: Arterial wall thickness measurements by B mode ultrasonography in patients with Takayasu's arteritis. Ann Rheum Dis 1996, 55:461-465.
97. Maeda B, Handa N, Matsumoto M, Hougaku H, Ogawa S, Oku N, Itoh T, Moriwaki H, Yoneda S, Kimura K, Kamada T: Carotid lesions detected by B-mode ultrasonography in Takayasu's arteritis: "macaroni sign" as an Indicator of the disease. Ultrasound Med Biol 1991, 17:695-701.
98. Hayashi K, Fukushima T, Matsunaga N, Zen-ichiro H: Takayasu's arteritis: decrease in aortic wall thickening following steroid therapy, documented by CT. Br J Radiol 1986, 59:281-283.
99. Tanigawa K, Eguchi K, Kitamura Y, Kawakami A, Ida H, Yamashita S, Matsunaga N, Hayashi K, Nagataki S: Magnetic resonance imaging detection of aortic and pulmonary artery wall thickening In the acute stage of Takayasu arteritis: Improvement of clinical and radiologic findings after steroid therapy. Arthritis Rheum 1992, 1992:476-480.
100. Flamm SD, VanDyke C, White RD, Hoffman GS: Novel magnetic resonance imaging (MRI) techniques for evaluating active arterial inflammation in Takayasu's disease [abstract]. Arthritis Rheum 1996, 39(suppl):S201.
101. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS: Treatment of glucocorticosteroid-resistant or relapsing Takayasu's arteritis with methotrexate. Arthritis Rheum 1994, 37:578-582.